Strategies for Achieving Healthy Vascular Aging

Kristen L. Nowak, Matthew J. Rossman, Michel Chonchol, Douglas R. Seals

The population is aging rapidly worldwide, which will lead to an increased societal and economic burden of age-associated chronic disease, including cardiovascular diseases.[1,2] Cardiovascular diseases remain the leading cause of morbidity and mortality in developed nations, and chronological age is the primary risk factor for cardiovascular diseases.[3] Arterial stiffness and blood pressure (BP) both increase with advancing age[4–7] and are independent predictors of cardiovascular (CV) events and mortality.[8,9] As such, there is strong, ongoing demand for evidence-based strategies that prevent, delay, or reverse age-associated increases in BP and arterial stiffness.[10,11] Indeed, the need for new approaches is expected to grow as the burden of age- and accelerated aging-associated cardiovascular dysfunction and disease continues to rise. In this review, we discuss the concept of healthy vascular aging (HVA) with regard to definition and contributing mechanisms, existing and promising HVA-enhancing lifestyle- and pharmacological-based strategies, and future directions. The focus will be primarily on data from observational and intervention studies in humans.

Components of HVA and Related Implications

Arterial stiffening and increases in BP occur with advancing age[4–7] although population-based studies indicate that this is not an inevitable consequence of aging but rather results from an industrialized lifestyle. [12,13] The prevalence of hypertension dramatically increases with advancing age, affecting approximately two thirds of Americans ≥60 years.[3] Hypertension is also highly prevalent in populations with chronic disease, including chronic kidney disease (CKD) and type 2 diabetes mellitus.[14,15] The most recent Joint National Commission 8 guidelines increased the BP treatment goal for individuals >60 years of age to <150/90 mm Hg with a goal of <140/90 mm Hg in adults 30 to 59 years of age, including individuals with diabetes mellitus and nondiabetic CKD.[16] However, the recently completed multicenter randomized controlled trial, SPRINT (Systolic Blood Pressure Intervention Trial), conducted nationwide in >9000 adults[17] challenged these guidelines. SPRINT was terminated early as a consequence of a 25% lower risk of the composite end point of CV events and death in individuals randomized to intensive BP lowering (systolic BP [SBP] <120 mm Hg) compared with standard treatment (SBP <140 mm Hg). Notably, this finding was persistent across subgroups, including CKD and older adults (≥75 years of age).[18] Although the technique used for BP measurement in SPRINT has been discussed,[19] the results of the trial have been influential because a new report from the American College of Cardiology and American Heart Association Task Force of Clinical Practice Guidelines now defines high BP as ≥130/80 mm Hg for all ages.[20]

Large elastic artery stiffening (ie, aorta and carotid arteries) also occurs with advancing age and is greater at any age in patients with chronic disease, including CKD,[21] diabetes mellitus,[22] and hypertension.[23] As a result, these and other clinical disorders featuring such CV changes can be viewed as states of accelerated vascular aging. Multiple techniques exist to assess arterial stiffness, including local distensibility (eg, ultrasound and tonometry-measured carotid artery compliance), the carotid or aortic augmentation index, aortic distensibility by magnetic resonance imaging, and pulse-wave velocity (PWV; assessed between 2 arterial segments), as reviewed elsewhere.[24–26] Of note, augmentation index is generally not considered an accurate marker of arterial stiffness because it is strongly influenced by heart rate, height, and contractility and decreases in older age.[24,25] As a result, augmentation index has not been included in the present assessment of the literature. Carotid-femoral PWV (CFPWV) is considered the gold-standard technique, measuring stiffness of the aorta,[27] and can be measured by applanation tonometry or Doppler flow recordings. Unlike arterial BP, no formal medical guidelines or targets exist for CFPWV nor is CFPWV routinely measured clinically; however, both 12 and 10 m/s have been suggested as cutoffs for increased risk of CV events.[27,28]

Arterial stiffness and BP/hypertension are dynamically interconnected, with each factor influencing the other in a bidirectional manner. Although arterial stiffness was long considered to be a complication of hypertension, there is growing evidence that arterial stiffening can precede the increase in SBP and that an elevation of SBP further augments arterial stiffness.[29–31]

Arterial stiffness increases in the aorta and carotid arteries with aging, with a lack of stiffening in the large peripheral muscular arteries, thus reducing peripheral impedance to the forward component of the arterial pulse-wave and increasing pulsatile energy transmission to the microcirculation.[32] This increased blood flow and pressure pulsatility can lead to damage of high flow, low impedance organs, including the kidneys and brain.[32] Indeed, increases in arterial stiffness are associated with declines in renal function[21,33] and are considered a hallmark of end-stage renal disease.[34] CFPWV is also independently associated with cognitive decline,[35,36] consistent with the concept of increased pulsatile energy transmission damaging the brain microcirculation and parenchymal tissues.

From the University of Colorado Anschutz Medical Campus, Aurora (K.L.N., M.C.); and University of Colorado Boulder (M.J.R., D.R.S.).
Correspondence to Kristen L. Nowak, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 12700 E 19th Ave C281, Aurora, CO 80045. E-mail Kristen.Nowak@ucdenver.edu

(*Hypertension*. 2018;71:389-402. DOI: 10.1161/HYPERTENSIONAHA.117.10439.)

Hypertension is available at http://hyper.ahajournals.org DOI: 10.1161/HYPERTENSIONAHA.117.10439



Figure 1. Components of healthy vascular aging. Higher blood pressure and stiffening of the large elastic arteries are associated with unhealthy vascular aging. With a shifting profile toward healthy vascular aging, blood pressure is lowered to a nonhypertensive range, and arterial stiffness is also reduced.

In addition, aortic stiffening–associated increases in pressure pulsatility and systolic load promote left ventricular remodeling featuring hypertrophy and dysfunction.[37,38]

Recently in this journal, Niiranen et al[39] demonstrated in a community-dwelling cohort of middle-aged and older (MA/O) adults from the Framingham Heart Study that HVA was independently associated with lower risk of incident CV events. HVA was defined as CFPWV <7.6 m/s (mean±2 SD of a reference group of individuals <30 years of age) in combination with absence of hypertension (using the previous guideline SBP/diastolic BP cutoff of 140/90 mm Hg; Figure 1). These findings are consistent with evidence that increased CFPWV is an independent predictor of incident CV events and mortality[8,9] and improves prediction over traditional risk factors alone, including BP.[8,40]

Building on the concept of HVA, this review will discuss mechanisms influencing HVA, as well as preventive strategies and therapeutic approaches for preserving/attaining HVA. Of note, few interventions have achieved HVA in individuals or groups that lack HVA status at baseline when applying the definition used in the Framingham Heart Study.[39] As such, we will include studies that achieved significant CFPWV lowering, with or without changes in BP, even if full restoration of HVA status was not attained. Last, although the Framingham Heart Study definition of HVA used SBP and diastolic BP to define BP component of this index, it should be emphasized that mean arterial pressure exerts an important physiological influence on arterial stiffness[41] and must be considered when assessing changes in CFPWV in response to the preventive and treatment strategies discussed below.

Mechanisms Influencing HVA

Modulation of BP With Aging

As the large elastic arteries become stiffer with aging, SBP increases, whereas diastolic BP decreases because of lessening of elastic recoil of the aorta[29,42]; as a result, pulse pressure widens with advancing age.[43] Isolated systolic hypertension is the most common form of hypertension in individuals ≥50 years.[44] Increases in large elastic artery stiffness are a major contributor to these changes in BP with aging, ultimately promoting the development of systolic hypertension.[29–31] Age-associated endothelial dysfunction featuring decreased nitric oxide (NO) bioavailability and increased endothelin-1 production, as well as dysregulated vascular tone, further contribute to increased SBP (Figure 2).[45,46] These events are mediated, in part, by increased oxidative stress associated with excessive superoxide production.[47] An interaction between the immune system and hypertension also may be involved because immune activation and inflammation promoted by oxidative stress are implicated in the development of hypertension.[48] In addition, with advancing age, sympathetic nervous system activity increases, and the association between sympathetic nervous system activity and BP becomes stronger, particularly in women.[49] Furthermore, chronic activation of the renin–angiotensin system promotes target organ damage, including the kidney and heart, because angiotensin II induces both increased BP and reactive oxygen species production.[50]

Modulation of Arterial Stiffness With Aging

Both functional and structural influences modulate arterial stiffness with aging. Functionally, arterial stiffness is modulated, in part, by the vasoconstrictor tone produced by the contractile state of vascular smooth muscle cells.[42] Age-associated vascular endothelial dysfunction interacts closely with arterial stiffness[51] as endothelial NO synthase uncoupling can promote vascular remodeling and increased arterial stiffness via decreased NO bioavailability,[52,53] which may be exacerbated by oxidative stress.[54,55] Age-associated neurohumoral dysfunction, resulting from decreased sympathetic baroreflex sensitivity and increased sympathetic activation, also promotes arterial stiffness, and vice-versa.[56] Systemic inflammation, which also increases with aging, may contribute to arterial stiffness via immune activation and the development of hypertension.[57]

Structurally, extracellular matrix remodeling alters the composition of elastin and collagen in the large elastic arteries with advancing age. The medial layer undergoes elastin fragmentation and degradation,[43,58] which is mediated,



Figure 2. Mechanisms influencing healthy vascular aging. Mechanisms influencing modulation of blood pressure with aging include vasodilation and vasoconstriction factors (eg, nitric oxide [NO] and endothelin-1 [ET-1]), immune activation and inflammation, sympathetic nervous system (SNS) activity, renin–angiotensin system (RAAS) activation, and oxidant signaling. Arterial stiffness is modulated by both functional (vascular smooth muscle cell tone) and structural components (extracellular matrix remodeling, including elastin degradation by matrix metalloproteinases [MMPs] and the formation of advanced glycation end products [AGEs]). ACE indicates angiotensin-converting enzyme; ANG, angiotensin; eNOS, endothelial NO synthase; and ROS, reactive oxygen species.

in part, by upregulation of matrix metalloproteinases.[59] Collagen deposition occurs, replacing the loss of elastin molecules,[43,58] and accelerated formation of advanced glycation end products promotes cross-linking of structural proteins and exacerbates increases in arterial stiffness.[60] Oxidative stress and inflammation drive these structural changes via vascular damage, smooth muscle cell proliferation, and arterial remodeling.[61,62] Angiotensin II may also modulate structural contributions to arterial stiffness by stimulating collagen formation, reducing elastin synthesis, and promoting matrix remodeling in addition to influencing NO signaling and reactive oxygen species production.[63]

Not only do changes in the extracellular matrix contribute to arterial stiffness, but intrinsic stiffening of the vascular smooth muscle cells, as measured by atomic force microscopy, also occurs with aging as well as hypertension.[64,65] Of note, intimal-medial thickening occurs with aging even in the absence of atherosclerotic plaques, mediated primarily by thickening of the intima,[10] and is positively correlated with CFPWV in older adults.[66,67] Age-associated disease processes, including diabetes mellitus (via impaired glucose tolerance)[68] and CKD (via vascular calcification),[69] can further exacerbate arterial stiffness.

It is difficult to separate hypertension and arterial stiffness because of their bidirectional interaction, common mechanisms, and overlapping presence in aging and age-associated disease. Although hypertension can promote aortic stiffening, large elastic artery stiffening may precede and promote an increase in SBP.[29,38] Large elastic artery stiffness is an independent predictor of incident hypertension in multiple longitudinal cohorts.[30,70,71] In addition, in rodents fed a high-fat, high-sucrose diet, increased aortic PWV is evident before an elevation in SBP.[31] Notably, there are some interventions that have reduced arterial stiffness in a manner deemed at least partially BP independent.[72–75] Although, in general, interventions with the most profound influence on CFPWV typically also demonstrate a large SBP-lowering effect, there are examples in which arterial stiffness is reduced without lowering SBP. Of note, most of these latter examples have tended to be in populations without hypertension. Arterial stiffness and BP may be even more tightly intertwined when BP is already elevated.

Lifestyle-Based Strategies to Maintain or Restore HVA

In this section, we will focus on lifestyle-based strategies (aerobic exercise, caloric restriction–based weight loss, and changes in diet composition) with evidence from randomized controlled trials demonstrating a reduction in CFPWV with or without changes in SBP. Using an approach used previously,[76] in Figure 3 we summarize current knowledge on the lifestyle-based strategies described below, including a semiquantitative assessment of the weight of the available evidence for efficacy based on our review of the relevant literature.

Aerobic Exercise

The original observation associating aerobic exercise with HVA is from 1993 in rigorously screened healthy adults (primarily men) who participated in the Baltimore Longitudinal Study of Aging.[77] In this cohort, CFPWV was lower in masters (MA/O) endurance trained athletes compared to sedentary peers, suggesting that aerobic exercise may attenuate the age-associated increase in arterial stiffness. Subsequently, a similar observation was made in postmenopausal women with normal BP.[78]

Consistent with these cross-sectional findings, intervention studies conducted in healthy MA/O adults have demonstrated a significant reduction in arterial stiffness with aerobic exercise training. This was first demonstrated as an improvement in carotid artery compliance after a 3-month walking program administered to men,[79] and later to postmenopausal women,[80] consistent with earlier evidence of reduced arterial stiffness with 4 weeks of exercise training in healthy young sedentary men.[81] Although a moderate intensity aerobic exercise intervention of similar duration was later shown to reduce CFPWV in healthy MA/O men[82] and women,[83] the reductions in CFPWV were small and not clearly independent of small decreases in BP. Moreover, no improvement in CFPWV with exercise was observed in a year-long study conducted in healthy older adults,[84] and similar findings were reported in a



Figure 3. Summary of healthy lifestyle-based strategies to maintain or restore healthy vascular aging. Note: under Effects, ↓ represents a reduction, ↔ represents weak or conflicting evidence, and (?) represents a lack of available data for the indicated outcome (for arterial stiffness, this refers specifically to data on carotid-femoral pulse-wave velocity). Under Evidence, the human symbol represents clinical evidence and the number of symbols reflects the approximate semiquantitative weight of evidence available for each strategy based on the authors' review of the literature. For details, see references/discussion in the text. DASH indicates Dietary Approaches to Stop Hypertension.

group of overweight MA/O adults.[85] In general, these trials on aerobic exercise and arterial stiffness in normotensive healthy adults reported little or no change in SBP.

The available evidence indicates a lack of efficacy of moderate intensity aerobic exercise for reducing CFPWV in MA/O adults with hypertension[86,87] although exercise has been reported to reduce CFPWV in young to middle-aged prehypertensive and hypertensive adults.[88] A recent meta-analysis of 14 aerobic exercise trials conducted in prehypertensive and hypertensive adults concluded that aerobic exercise does not reduce arterial stiffness although various indices of arterial stiffness were combined in this analysis.[89]

The efficacy of an aerobic exercise intervention to reduce arterial stiffness in the setting of age-associated disease is mixed. Although reductions in CFPWV and SBP have been observed with exercise training in adults with metabolic syndrome,[90] aerobic exercise has been reported to both lower and have no effect on CFPWV and SBP in MA/O adults with type 2 diabetes mellitus.[91,92] Similarly, aerobic exercise does not seem to reduce CFPWV or SBP in patients with moderate to severe CKD[93,94] although intradialytic exercise (ie, during a dialysis session) may be efficacious in chronic dialysis patients.[95]

Overall, aerobic exercise seems to be an evidence-based public health strategy for maintaining or restoring HVA in the setting of healthy (nonhypertensive) aging and in some diseases associated with accelerated vascular aging although there are some inconsistencies across studies. The improvements in CFPWV seem at times to be independent of any change in BP, particularly in healthy MA/O adults who are free from hypertension. Of note, in contrast to aerobic exercise, resistance exercise training does not seem to reduce arterial stiffness,[96] and intensive resistance exercise training performed without complementary aerobic exercise activities may actually increase CFPWV in young healthy individuals,[97] consistent with earlier cross-sectional observations.[98] Of note to public health translation, however, are data indicating limited adherence to aerobic exercise in long-term trials[99] and in accordance with federal activity guidelines.[100]

Weight Loss and Total Energy Intake

Short-term (ie, ≤3 months) caloric restriction–based weight loss administered in MA/O healthy overweight and obese adults significantly reduces CFPWV.[101–103] Similar improvements are observed with 1 year of caloric restriction–based weight loss.[104] The SBP-lowering effect in these trials was also notable (between 6 and 15 mm Hg in individuals free from hypertension at baseline). Caloric restriction–based weight loss is also efficacious for reducing CFPWV when administered in conjunction with other lifestyle interventions. Weight loss from an energy-restricted diet plus exercise reduces CFPWV and slightly decreases SBP in young overweight and obese adults.[105] In overweight and obese adults with moderately elevated SBP, caloric restriction–based weight loss in conjunction with the DASH (Dietary Approaches to Stop Hypertension) diet reduces both CFPWV and SBP.[106] Of note, these improvements may have been mediated, at least in part, by the 30% reduction in sodium intake associated with the diet rather than by weight loss alone. The combination of reduction in total energy intake, exercise, and sodium restriction also has a significant CFPWV- and SBP-lowering effect in young to middle-aged, normotensive, overweight and obese adults.[105,107] Similarly, in adults with type 2 diabetes mellitus, the combination of weight loss via energy restriction, exercise, and the weight loss medication Orlistat promotes a profound lowering of CFPWV.[108]

In contrast to a shorter-term caloric restriction–based weight loss intervention, lifelong caloric restriction is challenging in humans because of adherence and has risk of negative side effects (such as loss of bone density and lean muscle mass observed in the recent 2-year CALERIE [Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy] trial of 25% caloric restriction in nonobese, healthy, younger adults).[109] Nevertheless, lifelong caloric restriction in mice (40% reduction) prevents age-related increases in both aortic PWV and SBP.[110] In addition, in a case–control study in MA/O humans, those self-practicing caloric restriction (n=18) for an average of 6 years had substantially lower SBP than age-matched healthy controls consuming a typical American diet,[111] and preliminary

data indicate lower CFPWV as well in those practicing dietary restriction (Luigi Fontana, personal communication, 2017).

In summary, caloric restriction–based weight loss interventions have a consistent effect of reducing CFPWV and SBP and should be considered an important lifestyle-based strategy to restore or maintain HVA in overweight and obese adults. However, adherence to caloric restriction–based weight loss interventions in long-term trials[112] and maintenance of weight loss[113] are large challenges, perhaps limiting public health translation. Improvements in HVA status may be mediated, in part, through modification of dietary components, such as dietary sodium, which will be discussed more in the subsequent section, or via administration through a combination lifestyle program, such as with exercise. Further evidence is needed on the efficacy of this strategy in diseases of accelerated CV aging, such as CKD.

Dietary Components and Dietary Patterns

Dietary Sodium Restriction

The first observation linking dietary sodium intake to arterial stiffness is a case–control study from 1986, which compared CFPWV in normotensive adults who voluntarily followed a low-sodium diet (mean intake 44 mmol/d) for an average of 2 years to controls with the same mean arterial pressure. CFPWV was substantially lower in MA/O adults who practiced dietary sodium restriction.[114] Subsequently, 5 trials of dietary sodium restriction have been conducted with CFPWV as an end point in MA/O, healthy adults of varying SBP (normotensive to hypertensive).[87,115–118] CFPWV was significantly reduced in 4 of these trials,[87,116–118] and SBP was lowered in all 5. Of note, in 2 of these trials, individuals lacking HVA by the Framingham definition at baseline were restored to HVA status by dietary sodium restriction (Figure 4).[87,118] The efficacy of this intervention for restoring HVA is further supported by evidence that dietary sodium restriction rapidly improves carotid artery compliance, another index of arterial stiffness, in MA/O adults with moderately elevated SBP.[119]

Trials of dietary sodium restriction in populations of accelerated aging diseases are lacking. One crossover trial of dietary sodium restriction has been conducted in hypertensive patients with stages 3 to 4 CKD, which demonstrated a nonsignificant reduction of CFPWV with a strong SBP-lowering effect.[120] It also merits mention that sodium intake interacts closely with dietary potassium intake to influence CV risk.[121] Evidence on the effect of potassium supplementation on CFPWV in healthy adults is mixed,[72,122] and the interactions of dietary sodium and potassium intake on CFPWV warrant additional research. Overall, dietary sodium restriction has a consistent SBP-lowering effect and significantly reduces CFPWV in healthy MA/O adults. Thus, dietary sodium restriction represents an important public health strategy to maintain or restore HVA although further research is needed in populations with clinical disorders. Despite challenges in adhering to a low-sodium diet, policy changes implemented at a national level in Finland support that population-level reductions in dietary sodium intake are possible.[123]

Flavonoids

Flavonoids are low molecular weight compounds composed of a 3-ring structure with various substitutions and are found



Figure 4. Dietary sodium restriction restores healthy vascular aging (HVA). Changes in systolic blood pressure (SBP; **top**) and carotid-femoral pulse-wave velocity (CFPWV; **bottom**) in postmenopausal women (black bars) and postmenopausal women and middle-aged and older men (white bars) with elevated blood pressure in response to a low-sodium diet compared with normal sodium intake (30–50% restriction). Individuals lacking HVA by the Framingham definition at baseline were restored to HVA status by dietary sodium restriction in both studies, as indicated by the reductions in SBP and CFPWV from the red- to the green-shaded zone (above and below the dashed line). Data derived from Seals et al[87] and Jablonski et al.[118,183]

in abundance in citrus fruits, seeds, olive oil, tea, and red wine.[124] Isoflavones are 1 class of flavonoids, found most often in legumes, including soybeans.[125] Administration of isoflavones or an isoflavone metabolite reduces CFPWV in healthy MA/O men and postmenopausal women with or without altering SBP.[74,126] Flavanones, flavanols, and anthocyanins are other classes of flavonoids[124] with evidence of reducing CFPWV.[73,127–129] Grapefruit juice with high flavanones reduces CFPWV without lowering SBP in postmenopausal women with a large abdominal circumference.[73] Similarly, cocoa flavanols reduce CFPWV in healthy MA/O men,[127] as well as young healthy adults,[128] and postmenopausal women with type 2 diabetes mellitus,[129] along with possible reductions in SBP.[127,128] Finally, cranberry juice with anthocyanins and polyphenols reduces CFPWV without changing SBP in MA/O adults with coronary artery disease.[75] Thus, there is evidence that flavonoids may reduce CFPWV with or without changes in SBP. Notably, adverse reactions are rare. and flavonoids seem to have an exceptional safety record.[124]

Dietary Patterns

Specific patterns of dietary intake may modulate HVA. In a longitudinal cohort followed for 27 years, vegetable intake in childhood and persistently high consumption of fruits and

vegetable intake across the study period were independently associated with lower CFPWV in adulthood.[130] However, specific evidence on the effect of other dietary patterns, such as the Mediterranean or vegetarian diet on CFPWV, is currently lacking although alternate measurements of arterial stiffness suggest that such patterns may lead to improvements.[76] In trials implementing dietary patterns, including DASH, the Mediterranean diet, and high fruit and vegetable intake, BP is also significantly reduced.[131] This topic clearly represents an important and presently understudied area of future research.

Pharmacological-Based Strategies to Maintain or Restore HVA

Numerous pharmacological agents, both those routinely prescribed as well as novel agents, represent potential strategies for maintaining or restoring HVA. Agents that will be discussed in the upcoming sections include antihypertensive medications, statins, mammalian target of rapamycin (mTOR) inhibitors, AMP-activated protein kinase (AMPK) activators, sirtuin activators, anti-proinflammatory cytokine therapies, peroxisome proliferator–activated receptor-γ activators, and antifibrotic drugs. In Figure 5, we summarize current knowledge on the pharmacological strategies described below, including a semiquantitative assessment of the weight of the available evidence for efficacy based on our review of the relevant literature.

Antihypertensive Agents and BP Lowering

Trials evaluating the effect of antihypertensive agents on CFPWV have primarily been conducted in individuals with hypertension although additional evidence is provided from a few studies conducted in healthy volunteers.[132] Overall, most antihypertensive agents, including vasodilators,[133] β-blockers,[134,135] calcium channel blockers,[136,137] diuretics,[138] and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ARB),[138–141] seem to have some effect on CFPWV, with the best long-term evidence existing for angiotensin-converting enzyme inhibitors/ARB agents. Of note, β-blockers may be less useful because the slowing of heart rate (HR) can increase pulse pressure and central pressure augmentation.[142] Spironolactone also significantly lowers CFPWV in patients with stages 2 to 3 CKD already on angiotensin-converting enzyme inhibitors/ARBs with good BP control.[143]

It may be the degree of SBP lowering induced that is more important than the medication class on the effect on CFPWV. In SPRINT,[17] CFPWV was measured in a subgroup of participants in an ancillary study, including a large number of patients with CKD and adults ≥75 years of age. The data are pending but will provide important evidence on the influence of long-term BP control (regardless of medication class) on arterial stiffness. A small study conducted in nondiabetic, hypertensive older adults suggests that intensive BP control does more effectively reduce CFPWV than standard BP management.[144] However, despite well-known benefits of antihypertensive therapies, adherence is often suboptimal, particularly among older adults with multiple comorbid conditions, and both drug–drug and drug–disease interactions increase the risk of adverse events with advancing age.[145]

Statins

Numerous trials have assessed the effect of statins (HMG-CoA [3-hydroxy-3-methylglutaryl-coenzyme] reductase inhibitors) in CFPWV in MA/O adults with hypercholesterolemia, isolated systolic hypertension, or who are overweight/obese.[146–152] With the exception of 1 trial,[151] these studies have consistently reported significant reductions in CFPWV, generally without changing SBP.[146,148–150] The combination of a statin and an ARB also lowers CFPWV in healthy middle-aged men.[153] Overall, statins seem effective at lowering CFPWV without changing SBP in MA/O adults. Statins have a well-established



Figure 5. Summary of pharmacological-based strategies to maintain or restore healthy vascular aging. Note: under Effects, ↓ represents a reduction, ↔ represents weak or conflicting evidence, and (?) represents a lack of available data for the indicated outcome (for arterial stiffness, this refers specifically to data on carotid-femoral pulse-wave velocity). Under Evidence, human and mouse symbols represent clinical and preclinical evidence, respectively, and the number of symbols reflects the approximate semiquantitative weight of evidence available for each strategy based on the authors' review of the literature. For details, see references/discussion in the text. AMPK indicates AMP-activated protein kinase; HDL, high-density lipoprotein; IL-1β, interleukin-1 β; LDL, low-density lipoprotein; mTOR, mammalian target of rapamycin; PPAR-γ, peroxisome proliferator–activated receptor γ; SAC, sirtuin activating compound; and TNFα, tumor necrosis factor-α.

safety profile, although similar to antihypertensive agents, adherence can be suboptimal, particularly with advancing age.[145] Because both antihypertensive agents and statins are commonly prescribed medications with advancing age, they should be considered effective strategies to maintain or restore HVA. This conclusion also emphasizes the importance of considering these effects when studying the efficacy of other interventions in populations taking these agents at baseline.

mTOR Inhibitors, AMPK Activators, and Sirtuin Activators

With advancing age, nutrient sensing pathways, including mTOR, AMPK, and sirtuins, become dysregulated.[154] These pathways are among those modulated by chronic caloric restriction and, therefore, pharmacological manipulation might produce similar CV effects.[76,155] As such, interventions targeting these pathways may help maintain or restore HVA.

In a clinical trial that converted kidney transplant recipients from immunosuppression with cyclosporine A to the mTOR inhibitor sirolimus (both in addition to mycophenolate mofetil), conversion significantly reduced CFPWV, suggesting that mTOR inhibition reduces arterial stiffness.[156] BP was also reduced but may have been mediated by improved renal function and medication adjustments. The reduction in arterial stiffness is consistent with evidence that mTOR inhibition with rapamycin reduces aortic PWV in old mice (although without obviously changing BP).[157] However, rapamycin has notable side effects, including the potential for metabolic dysregulation, which may limit its CV health–promoting effects.[158] Consequently, safer analogs of rapamycin (rapalogs) are being developed as alternate therapies.[159]

The AMPK activator metformin is another potential novel therapy to maintain or restore HVA. As proof of concept, metformin reduces CFPWV and BP in young women with polycystic ovary syndrome and is also well tolerated,[160] thus may also reduce arterial stiffness in other states of impaired AMPK activation, including aging. Finally, sirtuin activators, including resveratrol and NAD^+ precursors, such as nicotinamide mononucleotide and nicotinamide riboside, are other potential strategies to reduce age-associated arterial stiffness. Resveratrol is a polyphenol found in red wine, grapes, and other berries and activates sirtuin-1.[155] In nonhuman primates, resveratrol ameliorates high-fat and high-sucrose diet-induced increases in aortic PWV without changing BP.[161] Resveratrol also inhibits the mTOR/S6 kinase pathway.[162] Of note, resveratrol may have off-target effects when administered in combination with other healthy lifestyle practices.[155] Another potential strategy to augment the age-associated decline in sirtuin-1 activity is to increase bioavailability of the cosubstrate NAD^+.[163] For example, supplementation with nicotinamide mononucleotide reduces aortic PWV without obviously changing BP in old mice,[164] and supplementation with nicotinamide riboside reduces BP and CFPWV in MA/O adults, particularly those with prehypertensive levels of SBP.[165] However, additional research about the efficacy of NAD^+ boosting and other sirtuin-activating compounds for reducing arterial stiffness in humans is needed, including data on clinical disorders of accelerating CV aging.

Anti-Proinflammatory Cytokine Therapies

Anti-proinflammatory cytokine therapies are a potential novel therapeutic to restore HVA. Tumor necrosis factor-α antagonism reduces CFPWV without changing BP in chronic inflammatory diseases associated with increased aortic stiffness, such as rheumatoid arthritis,[166–168] but the potential side effects of anti-proinflammatory cytokine therapies may limit use in healthy aging populations. Of note, in the recently completed CANTOS (Canakimumab Anti-Inflammatory Thrombosis Outcomes Study), which enrolled >10 000 patients with stable coronary artery disease and elevated C-reactive protein levels, the interleukin-1β inhibitor canakinumab significantly reduced risk of major CV events by 15%.[169] These results provide initial support for the efficacy of anti-proinflammatory therapies for treating (and potentially preventing) CV diseases and restoring HVA. However, the higher incidence of fatal infection observed with canakinumab may limit translation to a healthy again population.

Peroxisome Proliferator–Activated Receptor-γ Activation

Peroxisome proliferator–activated receptor-γ is a regulator of fatty acid storage and glucose metabolism and is activated by the thiazolidinedione pioglitazone. Short-term treatment with pioglitazone reduces brachial-ankle PWV in patients with type 2 diabetes mellitus[170] and carotid-radial PWV in obese men with impaired glucose tolerance,[171] without changing BP. However, the effects of these compounds on CFPWV and in the settings of age- and disease-associated arterial stiffening are currently unknown, and potential side effects of weight gain, edema, shortness of breath, and bone fracture need to be considered.[172]

Antifibrotic Agents

Pirfenidone is an antifibrotic agent that inhibits transforming growth factor-β, tumor necrosis factor-α, and other growth factors and interferes with matrix formation.[173] It is prescribed clinically to treat idiopathic pulmonary fibrosis and is generally safe with an acceptable side effect profile.[174] In a rodent model of diabetes mellitus, pirfenidone reverses cardiac fibrosis, attenuates cardiac stiffness, and also reduces renal fibrosis (without changing BP) and thus may hold promise in attenuating age-associated aortic stiffening.[175]

Overall, it is likely that novel pharmacological agents will have a future role in the treatment of diseases of accelerated vascular aging. Their use in the setting of healthy aging, to maintain or restore HVA, will require a more discerning consideration weighing potential side effects against potential benefits.

Mechanisms of Action

As discussed previously, arterial stiffness and elevated BP share common mechanisms and bidirectional interactions (Figure 2). In general, shorter duration interventions are more likely to modulate functional components of arterial stiffness (vascular smooth muscle tone) and to lower BP than to change arterial structure (eg, collagen or elastin composition) because the latter changes may require a long-term treatment period (eg, years) to induce.[79,110] Structural changes may be even more difficult to reverse in disease states, such as CKD, which is additionally characterized by medial calcification.[176]

Lifestyle-Based Strategies

We will focus this section on mechanisms by which lifestyle-based strategies may modulate arterial stiffness rather than BP, and the reader is referred elsewhere for a discussion of the latter.[177,178] Lifestyle-based strategies to maintain or restore HVA seem more likely to influence functional components of arterial stiffness although it is challenging to discern any structural changes that may occur if such interventions were maintained for a longer duration than typically evaluated in a randomized controlled trial.

Aerobic exercise likely influences functional components of arterial stiffness, such as increased NO production,[85] although long-term aerobic exercise may also influence arterial wall structure, including advanced glycation end products cross-linking of proteins.[179,180] Indeed, results from preclinical work in mice support the possibility that aerobic exercise may induce structural changes in the large elastic arteries of older animals, including reductions in collagen I and III, transforming growth factor-β1, and reduced smooth muscle α-actin.[181,182]

Collectively, regression analyses in trials of caloric restriction–based weight loss suggest that reductions in arterial stiffness are independent of BP changes. Improvements in stiffness in these studies over a relatively short time period (eg, 12 weeks) suggest that regulation of smooth muscle tone likely plays a larger role than structural changes. Functional influences on arterial stiffness, including NO production, may be mediated in part by reductions in circulating insulin or changes in other hormones, such as leptin.[183]

Reductions in arterial stiffness with caloric restriction–based weight loss may also be influenced by changes in diet composition, including dietary sodium restriction. Dietary sodium restriction rapidly improves carotid artery compliance, again suggesting a larger contribution of functional versus structural changes.[119] Indeed, dietary sodium restriction both reduces vascular oxidative stress and increases NO bioavailability in humans,[184] and rising sodium concentrations increase endothelial cell stiffness measured by atomic force microscopy, while downregulating NO production.[185] Reductions in the endogenous Na^+/K^+ ATPase inhibitor marinobufagenin may also modulate the reductions in CFPWV with dietary sodium restriction.[118]

At least with shorter-term administration, flavonoids seem to also modulate functional components of arterial stiffness. Isoflavones are vasodilatory, reducing endothelin-1, increasing NO bioavailability, and improving vascular endothelial function.[186] Flavanones may also increase NO bioavailability.[187] Finally, intake of fruits and vegetables may modulate arterial stiffness via the effects of individual bioactive nutrients and phytochemicals, as well as via reductions in oxidative stress, inflammation, and insulin resistance.[188,189]

Pharmacological-Based Strategies

Pharmacological-based strategies to maintain or restore HVA may modulate functional or structural components of arterial stiffness. Antihypertensive agents primarily target the functional (vasoconstrictive) component of arterial stiffness through a direct modulation of BP.[142] However angiotensin-converting enzyme inhibitors/ARBs may be particularly effective at reducing arterial stiffness and indeed are more efficacious in the long term than other antihypertensive agents because they also have antifibrotic effects.[190] Statins also modulate smooth muscle tone via increased NO bioavailability,[191] as well as reduced sympathetic neural activity[192] and oxidative stress.[193] Metformin promotes endothelial NO synthase activation by activating AMPK in the endothelium[194] and additionally inhibits nuclear factor κB signaling and decreases inflammation.[149] Metformin may also modify arterial stiffness and lower BP by promoting weight loss.[160]

Additional agents modulating functional regulation of arterial stiffness are rapamycin, which activates arterial AMPK and decreases oxidative stress,[157] and resveratrol, which increases endothelial NO synthase activity, reduces superoxide generation by NAD(P)H oxidases, and reduces nuclear factor κB–mediated inflammation and oxidative stress.[161,195,196] Further research is needed regarding underlying mechanisms by which NAD^+ precursor may reduce BP and aortic stiffness, but sirtuin-1 activation may be involved.[164] Anti-proinflammatory cytokine therapies likely lower arterial stiffness via anti-inflammatory effects,[167,168] and peroxisome proliferator–activated receptor-γ activation also reduces circulating markers of inflammation.[170,171] Pharmacological agents may also target structural components of arterial stiffness, in particular antifibrotic agents.[142] Rapamycin also decreases collagen and advanced glycation end products in the aorta, suggesting reduced cross-linking of collagens by advanced glycation end products with treatment.[157]

Conclusions and Future Directions

In this review, we have discussed the concept of HVA and contributing mechanisms while also summarizing lifestyle- and pharmacological-based strategies to maintain or restore HVA in both healthy adults and patients with accelerated CV aging-related clinical disorders. There are notable gaps in the currently available research literature on this topic and practical challenges to implementing these interventions (Figure 6). In



Figure 6. Current gaps in knowledge and challenges related to establishing evidence-based strategies for healthy vascular aging.

particular, there remains an unmet need to translate effective strategies to maintain or restore HVA in the clinic and at the public health level. An example of this is the ongoing effort to reduce sodium intake at a population level through policy statements,[197] including government-industry partnerships to reduce sodium intake in several countries, including Japan, Finland, and the United Kingdom.[198] At the same time, preclinical models should continue to be used to discern the mechanisms modulating HVA in both healthy aging and diseased populations (reverse translation).[199] Indeed, the combination of forward and reverse translational physiological approaches has been used effectively to better understand the mechanisms by which prevention and treatment strategies, such as dietary sodium restriction, modulate BP and vascular health.[199]

Novel strategies to maintain or restore HVA continue to be developed and tested. Examples of promising lifestyle interventions include inspiratory muscle strength training (breathing against a resistive load), which lowers SBP in both normotensive adults and patients with sleep apnea,[200,201] passive heat therapy, which lowers mean arterial BP and CFPWV even in young healthy adults,[202] and novel dietary interventions that may mimic the beneficial effects of long-term caloric restriction, including different forms of intermittent fasting.[155] New pharmacological agents also continue to be developed, including anti-proinflammatory cytokine therapeutics and antisenescence drugs. In addition, in individuals with type 2 diabetes mellitus and established cardiovascular disease, a selective sodium-glucose cotransporter inhibitor (empaglifozin) was recently shown to influence properties related to arterial stiffness while lowering SBP, thus may hold promise to maintain or restore HVA.[203]

Notably, in the Framingham Heart study, only ≈1% of individuals >70 years of age met the criteria for HVA.[39] This observation highlights that it is difficult to maintain HVA into older age and that trials testing the efficacy of novel strategies are particularly needed for older adults. The recent SPRINT trial results indicate that this age group can indeed be responsive to an intervention, contrary to what may have been thought previously.[17] This was also the case for populations at high CV risk, including individuals with CKD. Thus, testing of novel interventions to restore HVA is also critically needed in diseases of accelerated CV aging, such as CKD and diabetes mellitus. An increased number of cardiovascular risk factors is also associated with a greater annual increase in CFPWV, thus likely contributing to the progressive reduction in the prevalence of HVA with advancing age.[204] Ultimately, shifting the distribution to a higher number of individuals with HVA status will reduce the burden of CV events and mortality in the population.

Acknowledgments

We thank Erzsebet Nagy for her contributions to the figures.

Sources of Funding

This work was supported by the National Heart, Lung and Blood Institute, R01HL134887, National Institutes on Aging, R01AG013038 and F32AG053009, and National Institute of Diabetes and Digestive and Kidney Diseases, K01DK103678 and R01DK094796.

Disclosures

None.

References

1. Heidenreich PA, Trogdon JG, Khavjou OA, et al; American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. *Circulation*. 2011;123:933–944. doi: 10.1161/CIR.0b013e31820a55f5.
2. Harper S. Economic and social implications of aging societies. *Science*. 2014;346:587–591. doi: 10.1126/science.1254405.
3. Benjamin EJ, Blaha MJ, Chiuve SE, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. *Circulation*. 2017;135:e146–e603. doi: 10.1161/CIR.0000000000000485.
4. Avolio AP, Chen SG, Wang RP, Zhang CL, Li MF, O'Rourke MF. Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. *Circulation*. 1983;68:50–58.
5. Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, Vasan RS, Levy D. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. *Hypertension*. 2004;43:1239–1245. doi: 10.1161/01.HYP.0000128420.01881.aa.
6. Mitchell GF, Wang N, Palmisano JN, Larson MG, Hamburg NM, Vita JA, Levy D, Benjamin EJ, Vasan RS. Hemodynamic correlates of blood pressure across the adult age spectrum: noninvasive evaluation in the Framingham Heart Study. *Circulation*. 2010;122:1379–1386. doi: 10.1161/CIRCULATIONAHA.109.914507.
7. McEniery CM, Yasmin, Maki-Petaja KM, McDonnell BJ, Munnery M, Hickson SS, Franklin SS, Cockcroft JR, Wilkinson IB; Anglo-Cardiff Collaboration Trial Investigators. The impact of cardiovascular risk factors on aortic stiffness and wave reflections depends on age: the Anglo-Cardiff Collaborative Trial (ACCT III). *Hypertension*. 2010;56:591–597. doi: 10.1161/HYPERTENSIONAHA.110.156950.
8. Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. *J Am Coll Cardiol*. 2014;63:636–646. doi: 10.1016/j.jacc.2013.09.063.
9. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. *J Am Coll Cardiol.* 2010;55:1318–1327.
10. Najjar SS, Scuteri A, Lakatta EG. Arterial aging: is it an immutable cardiovascular risk factor? *Hypertension*. 2005;46:454–462.
11. Lakatta EG. Cardiovascular aging research: the next horizons. *J Am Geriatr Soc*. 1999;47:613–625.
12. Avolio AP, Deng FQ, Li WQ, Luo YF, Huang ZD, Xing LF, O'Rourke MF. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China. *Circulation*. 1985;71:202–210.
13. Oliver WJ, Cohen EL, Neel JV. Blood pressure, sodium intake, and sodium related hormones in the Yanomamo indians, a "no-salt" culture. *Circulation*. 1975;52:146–151.
14. Kidney Disease: Improving Global Outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl*. 2012;2:337–414.
15. Colosia AD, Palencia R, Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. *Diabetes Metab Syndr Obes*. 2013;6:327–338.
16. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311:507–520. doi: 10.1001/jama.2013.284427.
17. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. *New Engl J Med*. 2015;373:2103–2116.
18. Williamson JD, Supiano MA, Applegate WB, et al; SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. *JAMA*. 2016;315:2673–2682. doi: 10.1001/jama.2016.7050.
19. Myers MG, Campbell NR. Unfounded concerns about the use of automated office blood pressure measurement in SPRINT. *J Am Soc Hypertens*. 2016;10:903–905. doi: 10.1016/j.jash.2016.10.003.

20. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published online ahead of print November 13, 2017]. *Hypertension*. doi: 10.1161/HYP.0000000000000066. http://hyper.ahajournals.org/content/early/2017/11/10/HYP.0000000000000066.
21. Wang MC, Tsai WC, Chen JY, Huang JJ. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. *Am J Kidney Dis*. 2005;45:494–501. doi: 10.1053/j.ajkd.2004.11.011.
22. De Angelis L, Millasseau SC, Smith A, Viberti G, Jones RH, Ritter JM, Chowienczyk PJ. Sex differences in age-related stiffening of the aorta in subjects with type 2 diabetes. *Hypertension*. 2004;44:67–71. doi: 10.1161/01.HYP.0000130482.81883.fd.
23. AlGhatrif M, Strait JB, Morrell CH, Canepa M, Wright J, Elango P, Scuteri A, Najjar SS, Ferrucci L, Lakatta EG. Longitudinal trajectories of arterial stiffness and the role of blood pressure: the Baltimore Longitudinal Study of Aging. *Hypertension*. 2013;62:934–941. doi: 10.1161/HYPERTENSIONAHA.113.01445.
24. Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH. Aortic stiffness: current understanding and future directions. *J Am Coll Cardiol*. 2011;57:1511–1522. doi: 10.1016/j.jacc.2010.12.017.
25. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. *Arterioscler Thromb Vasc Biol*. 2003;23:554–566. doi: 10.1161/01.ATV.0000060460.52916.D6.
26. Van Bortel LM, Duprez D, Starmans-Kool MJ, Safar ME, Giannattasio C, Cockcroft J, Kaiser DR, Thuillez C. Clinical applications of arterial stiffness, Task Force III: recommendations for user procedures. *Am J Hypertens*. 2002;15:445–452.
27. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, Filipovsky J, Huybrechts S, Mattace-Raso FU, Protogerou AD, Schillaci G, Segers P, Vermeersch S, Weber T; Artery Society; European Society of Hypertension Working Group on Vascular Structure and Function; European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. *J Hypertens*. 2012;30:445–448. doi: 10.1097/HJH.0b013e32834fa8b0.
28. Mancia G, De Backer G, Dominiczak A, et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007;25:1105–1187. doi: 10.1097/HJH.0b013e3281fc975a.
29. Mitchell GF. Arterial stiffness and hypertension: chicken or egg? *Hypertension*. 2014;64:210–214. doi: 10.1161/HYPERTENSIONAHA.114.03449.
30. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, Benjamin EJ, Vasan RS, Mitchell GF. Aortic stiffness, blood pressure progression, and incident hypertension. *JAMA*. 2012;308:875–881. doi: 10.1001/2012.jama.10503.
31. Weisbrod RM, Shiang T, Al Sayah L, Fry JL, Bajpai S, Reinhart-King CA, Lob HE, Santhanam L, Mitchell G, Cohen RA, Seta F. Arterial stiffening precedes systolic hypertension in diet-induced obesity. *Hypertension*. 2013;62:1105–1110. doi: 10.1161/HYPERTENSIONAHA.113.01744.
32. Mitchell GF. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. *J Appl Physiol (1985)*. 2008;105:1652–1660. doi: 10.1152/japplphysiol.90549.2008.
33. Matsuda N, Takei T, Fujiu A, Ogawa T, Nitta K. Arterial stiffness in patients with non-diabetic chronic kidney disease (CKD). *J Atheroscler Thromb*. 2009;16:57–62.
34. Safar ME, London GM, Plante GE. Arterial stiffness and kidney function. *Hypertension*. 2004;43:163–168. doi: 10.1161/01.HYP.0000114571.75762.b0.
35. Waldstein SR, Rice SC, Thayer JF, Najjar SS, Scuteri A, Zonderman AB. Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. *Hypertension*. 2008;51:99–104. doi: 10.1161/HYPERTENSIONAHA.107.093674.
36. Scuteri A, Tesauro M, Appolloni S, Preziosi F, Brancati AM, Volpe M. Arterial stiffness as an independent predictor of longitudinal changes in cognitive function in the older individual. *J Hypertens*. 2007;25:1035–1040. doi: 10.1097/HJH.0b013e3280895b55.
37. Tan J, Pei Y, Hua Q, Xing X, Wen J. Aortic pulse wave velocity is associated with measures of subclinical target organ damage in patients with mild hypertension. *Cell Biochem Biophys*. 2014;70:167–171. doi: 10.1007/s12013-014-9876-9.
38. Mitchell GF. Arterial stiffness and hypertension. *Hypertension*. 2014;64:13–18. doi: 10.1161/HYPERTENSIONAHA.114.00921.
39. Niiranen TJ, Lyass A, Larson MG, Hamburg NM, Benjamin EJ, Mitchell GF, Vasan RS. Prevalence, correlates, and prognosis of healthy vascular aging in a Western Community-Dwelling Cohort: the Framingham Heart Study. *Hypertension*. 2017;70:267–274. doi: 10.1161/HYPERTENSIONAHA.117.09026.
40. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. *Circulation*. 2006;113:664–670. doi: 10.1161/CIRCULATIONAHA.105.579342.
41. Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, Heffernan KS, Lakatta EG, McEniery CM, Mitchell GF, Najjar SS, Nichols WW, Urbina EM, Weber T; American Heart Association Council on Hypertension. Recommendations for improving and standardizing vascular research on arterial stiffness: a scientific statement from the American Heart Association. *Hypertension*. 2015;66:698–722. doi: 10.1161/HYP.0000000000000033.
42. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. *Circulation*. 2003;107:139–146.
43. Lakatta EG, Mitchell JH, Pomerance A, Rowe GG. Human aging: changes in structure and function. *J Am Coll Cardiol*. 1987;10:42A–47A.
44. Franklin SS, Jacobs MJ, Wong ND, L'Italien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. *Hypertension*. 2001;37:869–874.
45. Stauffer BL, Westby CM, DeSouza CA. Endothelin-1, aging and hypertension. *Curr Opin Cardiol*. 2008;23:350–355. doi: 10.1097/HCO.0b013e328302f3c6.
46. Higashi Y, Kihara Y, Noma K. Endothelial dysfunction and hypertension in aging. *Hypertens Res*. 2012;35:1039–1047. doi: 10.1038/hr.2012.138.
47. Zalba G, San José G, Moreno MU, Fortuño MA, Fortuño A, Beaumont FJ, Díez J. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. *Hypertension*. 2001;38:1395–1399.
48. Wu J, Saleh MA, Kirabo A, et al. Immune activation caused by vascular oxidation promotes fibrosis and hypertension. *J Clin Invest*. 2016;126:50–67. doi: 10.1172/JCI80761.
49. Narkiewicz K, Phillips BG, Kato M, Hering D, Bieniaszewski L, Somers VK. Gender-selective interaction between aging, blood pressure, and sympathetic nerve activity. *Hypertension*. 2005;45:522–525. doi: 10.1161/01.HYP.0000160318.46725.46.
50. Conti S, Cassis P, Benigni A. Aging and the renin-angiotensin system. *Hypertension*. 2012;60:878–883. doi: 10.1161/HYPERTENSIONAHA.110.155895.
51. McEniery CM, Wallace S, Mackenzie IS, McDonnell B, Yasmin, Newby DE, Cockcroft JR, Wilkinson IB. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. *Hypertension*. 2006;48:602–608. doi: 10.1161/01.HYP.0000239206.64270.5f.
52. Oelze M, Kröller-Schön S, Steven S, et al. Glutathione peroxidase-1 deficiency potentiates dysregulatory modifications of endothelial nitric oxide synthase and vascular dysfunction in aging. *Hypertension*. 2014;63:390–396. doi: 10.1161/HYPERTENSIONAHA.113.01602.
53. Soucy KG, Ryoo S, Benjo A, Lim HK, Gupta G, Sohi JS, Elser J, Aon MA, Nyhan D, Shoukas AA, Berkowitz DE. Impaired shear stress-induced nitric oxide production through decreased NOS phosphorylation contributes to age-related vascular stiffness. *J Appl Physiol (1985)*. 2006;101:1751–1759. doi: 10.1152/japplphysiol.00138.2006.
54. Moreau KL, Gavin KM, Plum AE, Seals DR. Ascorbic acid selectively improves large elastic artery compliance in postmenopausal women. *Hypertension*. 2005;45:1107–1112. doi: 10.1161/01.HYP.0000165678.63373.8c.
55. Taddei S, Virdis A, Ghiadoni L, Salvetti G, Bernini G, Magagna A, Salvetti A. Age-related reduction of NO availability and oxidative stress in humans. *Hypertension*. 2001;38:274–279.
56. Okada Y, Galbreath MM, Shibata S, Jarvis SS, VanGundy TB, Meier RL, Vongpatanasin W, Levine BD, Fu Q. Relationship between sympathetic baroreflex sensitivity and arterial stiffness in elderly men and women. *Hypertension*. 2012;59:98–104. doi: 10.1161/HYPERTENSIONAHA.111.176560.
57. Ryan MJ. An update on immune system activation in the pathogenesis of hypertension. *Hypertension*. 2013;62:226–230. doi: 10.1161/HYPERTENSIONAHA.113.00603.

58. Sun Z. Aging, arterial stiffness, and hypertension. *Hypertension*. 2015;65:252–256. doi: 10.1161/HYPERTENSIONAHA.114.03617.
59. Wang M, Zhang J, Telljohann R, Jiang L, Wu J, Monticone RE, Kapoor K, Talan M, Lakatta EG. Chronic matrix metalloproteinase inhibition retards age-associated arterial proinflammation and increase in blood pressure. *Hypertension*. 2012;60:459–466. doi: 10.1161/HYPERTENSIONAHA.112.191270.
60. Semba RD, Nicklett EJ, Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype? *J Gerontol A Biol Sci Med Sci*. 2010;65:963–975. doi: 10.1093/gerona/glq074.
61. Touyz RM. Oxidative stress and vascular damage in hypertension. *Curr Hypertens Rep*. 2000;2:98–105.
62. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. *Hypertension*. 2001;38(3 pt 2):581–587.
63. Lyle AN, Raaz U. Killing me unsoftly: causes and mechanisms of arterial stiffness. *Arterioscler Thromb Vasc Biol*. 2017;37:e1–e11. doi: 10.1161/ATVBAHA.116.308563.
64. Qiu H, Zhu Y, Sun Z, Trzeciakowski JP, Gansner M, Depre C, Resuello RR, Natividad FF, Hunter WC, Genin GM, Elson EL, Vatner DE, Meininger GA, Vatner SF. Short communication: vascular smooth muscle cell stiffness as a mechanism for increased aortic stiffness with aging. *Circ Res*. 2010;107:615–619. doi: 10.1161/CIRCRESAHA.110.221846.
65. Sehgel NL, Sun Z, Hong Z, Hunter WC, Hill MA, Vatner DE, Vatner SF, Meininger GA. Augmented vascular smooth muscle cell stiffness and adhesion when hypertension is superimposed on aging. *Hypertension*. 2015;65:370–377. doi: 10.1161/HYPERTENSIONAHA.114.04456.
66. van Popele NM, Grobbee DE, Bots ML, Asmar R, Topouchian J, Reneman RS, Hoeks AP, van der Kuip DA, Hofman A, Witteman JC. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. *Stroke*. 2001;32:454–460.
67. Mackey RH, Sutton-Tyrrell K, Vaitkevicius PV, Sakkinen PA, Lyles MF, Spurgeon HA, Lakatta EG, Kuller LH. Correlates of aortic stiffness in elderly individuals: a subgroup of the Cardiovascular Health Study. *Am J Hypertens*. 2002;15(1 pt 1):16–23.
68. Salomaa V, Riley W, Kark JD, Nardo C, Folsom AR. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study. *Circulation*. 1995;91:1432–1443.
69. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. *Nephrol Dial Transplant*. 2008;23:586–593. doi: 10.1093/ndt/gfm660.
70. Dernellis J, Panaretou M. Aortic stiffness is an independent predictor of progression to hypertension in nonhypertensive subjects. *Hypertension*. 2005;45:426–431. doi: 10.1161/01.HYP.0000157818.58878.93.
71. Najjar SS, Scuteri A, Shetty V, Wright JG, Muller DC, Fleg JL, Spurgeon HP, Ferrucci L, Lakatta EG. Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. *J Am Coll Cardiol*. 2008;51:1377–1383. doi: 10.1016/j.jacc.2007.10.065.
72. He FJ, Marciniak M, Carney C, Markandu ND, Anand V, Fraser WD, Dalton RN, Kaski JC, MacGregor GA. Effects of potassium chloride and potassium bicarbonate on endothelial function, cardiovascular risk factors, and bone turnover in mild hypertensives. *Hypertension*. 2010;55:681–688. doi: 10.1161/HYPERTENSIONAHA.109.147488.
73. Habauzit V, Verny MA, Milenkovic D, Barber-Chamoux N, Mazur A, Dubray C, Morand C. Flavanones protect from arterial stiffness in postmenopausal women consuming grapefruit juice for 6 mo: a randomized, controlled, crossover trial. *Am J Clin Nutr*. 2015;102:66–74. doi: 10.3945/ajcn.114.104646.
74. Teede HJ, McGrath BP, DeSilva L, Cehun M, Fassoulakis A, Nestel PJ. Isoflavones reduce arterial stiffness: a placebo-controlled study in men and postmenopausal women. *Arterioscler Thromb Vasc Biol*. 2003;23:1066–1071. doi: 10.1161/01.ATV.0000072967.97296.4A.
75. Dohadwala MM, Holbrook M, Hamburg NM, Shenouda SM, Chung WB, Titas M, Kluge MA, Wang N, Palmisano J, Milbury PE, Blumberg JB, Vita JA. Effects of cranberry juice consumption on vascular function in patients with coronary artery disease. *Am J Clin Nutr*. 2011;93:934–940. doi: 10.3945/ajcn.110.004242.
76. LaRocca TJ, Martens CR, Seals DR. Nutrition and other lifestyle influences on arterial aging. *Ageing Res Rev*. 2017;39:106–119. doi: 10.1016/j.arr.2016.09.002.
77. Vaitkevicius PV, Fleg JL, Engel JH, O'Connor FC, Wright JG, Lakatta LE, Yin FC, Lakatta EG. Effects of age and aerobic capacity on arterial stiffness in healthy adults. *Circulation*. 1993;88(4 pt 1):1456–1462.
78. Tanaka H, DeSouza CA, Seals DR. Absence of age-related increase in central arterial stiffness in physically active women. *Arterioscler Thromb Vasc Biol*. 1998;18:127–132.
79. Tanaka H, Dinenno FA, Monahan KD, Clevenger CM, DeSouza CA, Seals DR. Aging, habitual exercise, and dynamic arterial compliance. *Circulation*. 2000;102:1270–1275.
80. Moreau KL, Donato AJ, Seals DR, DeSouza CA, Tanaka H. Regular exercise, hormone replacement therapy and the age-related decline in carotid arterial compliance in healthy women. *Cardiovasc Res*. 2003;57:861–868.
81. Cameron JD, Dart AM. Exercise training increases total systemic arterial compliance in humans. *Am J Physiol*. 1994;266(2 pt 2):H693–H701.
82. Hayashi K, Sugawara J, Komine H, Maeda S, Yokoi T. Effects of aerobic exercise training on the stiffness of central and peripheral arteries in middle-aged sedentary men. *Jpn J Physiol*. 2005;55:235–239. doi: 10.2170/jjphysiol.S2116.
83. Yoshizawa M, Maeda S, Miyaki A, Misono M, Saito Y, Tanabe K, Kuno S, Ajisaka R. Effect of 12 weeks of moderate-intensity resistance training on arterial stiffness: a randomised controlled trial in women aged 32-59 years. *Br J Sports Med*. 2009;43:615–618. doi: 10.1136/bjsm.2008.052126.
84. Oudegeest-Sander MH, Olde Rikkert MG, Smits P, Thijssen DH, van Dijk AP, Levine BD, Hopman MT. The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial. *Exp Gerontol*. 2013;48:1509–1517. doi: 10.1016/j.exger.2013.10.009.
85. Kearney TM, Murphy MH, Davison GW, O'Kane MJ, Gallagher AM. Accumulated brisk walking reduces arterial stiffness in overweight adults: evidence from a randomized control trial. *J Am Soc Hypertens*. 2014;8:117–126. doi: 10.1016/j.jash.2013.10.001.
86. Ferrier KE, Waddell TK, Gatzka CD, Cameron JD, Dart AM, Kingwell BA. Aerobic exercise training does not modify large-artery compliance in isolated systolic hypertension. *Hypertension*. 2001;38:222–226.
87. Seals DR, Tanaka H, Clevenger CM, Monahan KD, Reiling MJ, Hiatt WR, Davy KP, DeSouza CA. Blood pressure reductions with exercise and sodium restriction in postmenopausal women with elevated systolic pressure: role of arterial stiffness. *J Am Coll Cardiol*. 2001;38:506–513.
88. Collier SR, Kanaley JA, Carhart R Jr, Frechette V, Tobin MM, Hall AK, Luckenbaugh AN, Fernhall B. Effect of 4 weeks of aerobic or resistance exercise training on arterial stiffness, blood flow and blood pressure in pre- and stage-1 hypertensives. *J Hum Hypertens*. 2008;22:678–686. doi: 10.1038/jhh.2008.36.
89. Montero D, Roche E, Martinez-Rodriguez A. The impact of aerobic exercise training on arterial stiffness in pre- and hypertensive subjects: a systematic review and meta-analysis. *Int J Cardiol*. 2014;173:361–368. doi: 10.1016/j.ijcard.2014.03.072.
90. Donley DA, Fournier SB, Reger BL, DeVallance E, Bonner DE, Olfert IM, Frisbee JC, Chantler PD. Aerobic exercise training reduces arterial stiffness in metabolic syndrome. *J Appl Physiol (1985)*. 2014;116:1396–1404. doi: 10.1152/japplphysiol.00151.2014.
91. Madden KM, Lockhart C, Cuff D, Potter TF, Meneilly GS. Aerobic training-induced improvements in arterial stiffness are not sustained in older adults with multiple cardiovascular risk factors. *J Hum Hypertens*. 2013;27:335–339. doi: 10.1038/jhh.2012.38.
92. Madden KM, Lockhart C, Cuff D, Potter TF, Meneilly GS. Short-term aerobic exercise reduces arterial stiffness in older adults with type 2 diabetes, hypertension, and hypercholesterolemia. *Diabetes Care*. 2009;32:1531–1535. doi: 10.2337/dc09-0149.
93. Headley S, Germain M, Wood R, Joubert J, Milch C, Evans E, Poindexter A, Cornelius A, Brewer B, Pescatello LS, Parker B. Short-term aerobic exercise and vascular function in CKD stage 3: a randomized controlled trial. *Am J Kidney Dis*. 2014;64:222–229. doi: 10.1053/j.ajkd.2014.02.022.
94. Howden EJ, Leano R, Petchey W, Coombes JS, Isbel NM, Marwick TH. Effects of exercise and lifestyle intervention on cardiovascular function in CKD. *Clin J Am Soc Nephrol*. 2013;8:1494–1501. doi: 10.2215/CJN.10141012.
95. Toussaint ND, Polkinghorne KR, Kerr PG. Impact of intradialytic exercise on arterial compliance and B-type natriuretic peptide levels in hemodialysis patients. *Hemodial Int*. 2008;12:254–263. doi: 10.1111/j.1542-4758.2008.00262.x.
96. Miyachi M. Effects of resistance training on arterial stiffness: a meta-analysis. *Br J Sports Med*. 2013;47:393–396. doi: 10.1136/bjsports-2012-090488.
97. Cortez-Cooper MY, DeVan AE, Anton MM, Farrar RP, Beckwith KA, Todd JS, Tanaka H. Effects of high intensity resistance training on arterial stiffness and wave reflection in women. *Am J Hypertens*. 2005;18:930–934. doi: 10.1016/j.amjhyper.2005.01.008.

98. Bertovic DA, Waddell TK, Gatzka CD, Cameron JD, Dart AM, Kingwell BA. Muscular strength training is associated with low arterial compliance and high pulse pressure. *Hypertension*. 1999;33:1385–1391.
99. Saida TGRH, Juul Sørensen T, Langberg H. Long-term exercise adherence after public health training in at-risk adults. *Ann Phys Rehabil Med*. 2017;60:237–243. doi: 10.1016/j.rehab.2017.02.006.
100. Ward BW, Clarke TC, Nugent NC, Schiller JS. Early Release of Selected Estimates Based on Data from the 2015 National Health Interview Survey. National Center for Health Statistics. https://www.cdc.gov/nchs/data/nhis/earlyrelease/earlyrelease201605.pdf. Accessed December 14, 2017.
101. Dengo AL, Dennis EA, Orr JS, Marinik EL, Ehrlich E, Davy BM, Davy KP. Arterial destiffening with weight loss in overweight and obese middle-aged and older adults. *Hypertension*. 2010;55:855–861. doi: 10.1161/HYPERTENSIONAHA.109.147850.
102. Keogh JB, Brinkworth GD, Noakes M, Belobrajdic DP, Buckley JD, Clifton PM. Effects of weight loss from a very-low-carbohydrate diet on endothelial function and markers of cardiovascular disease risk in subjects with abdominal obesity. *Am J Clin Nutr*. 2008;87:567–576.
103. Clifton PM, Keogh JB, Foster PR, Noakes M. Effect of weight loss on inflammatory and endothelial markers and FMD using two low-fat diets. *Int J Obes (Lond)*. 2005;29:1445–1451. doi: 10.1038/sj.ijo.0803039.
104. Wycherley TP, Brinkworth GD, Keogh JB, Noakes M, Buckley JD, Clifton PM. Long-term effects of weight loss with a very low carbohydrate and low fat diet on vascular function in overweight and obese patients. *J Intern Med*. 2010;267:452–461. doi: 10.1111/j.1365-2796.2009.02174.x.
105. Cooper JN, Buchanich JM, Youk A, Brooks MM, Barinas-Mitchell E, Conroy MB, Sutton-Tyrrell K. Reductions in arterial stiffness with weight loss in overweight and obese young adults: potential mechanisms. *Atherosclerosis*. 2012;223:485–490. doi: 10.1016/j.atherosclerosis.2012.05.022.
106. Blumenthal JA, Babyak MA, Hinderliter A, Watkins LL, Craighead L, Lin PH, Caccia C, Johnson J, Waugh R, Sherwood A. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. *Arch Intern Med*. 2010;170:126–135. doi: 10.1001/archinternmed.2009.470.
107. Hughes TM, Althouse AD, Niemczyk NA, Hawkins MS, Kuipers AL, Sutton-Tyrrell K. Effects of weight loss and insulin reduction on arterial stiffness in the SAVE trial. *Cardiovasc Diabetol*. 2012;11:114. doi: 10.1186/1475-2840-11-114.
108. Barinas-Mitchell E, Kuller LH, Sutton-Tyrrell K, Hegazi R, Harper P, Mancino J, Kelley DE. Effect of weight loss and nutritional intervention on arterial stiffness in type 2 diabetes. *Diabetes Care*. 2006;29:2218–2222. doi: 10.2337/dc06-0665.
109. Villareal DT, Fontana L, Das SK, Redman L, Smith SR, Saltzman E, Bales C, Rochon J, Pieper C, Huang M, Lewis M, Schwartz AV; CALERIE Study Group. Effect of two-year caloric restriction on bone metabolism and bone mineral density in non-obese younger adults: a randomized clinical trial. *J Bone Miner Res*. 2016;31:40–51. doi: 10.1002/jbmr.2701.
110. Donato AJ, Walker AE, Magerko KA, Bramwell RC, Black AD, Henson GD, Lawson BR, Lesniewski LA, Seals DR. Life-long caloric restriction reduces oxidative stress and preserves nitric oxide bioavailability and function in arteries of old mice. *Aging Cell*. 2013;12:772–783. doi: 10.1111/acel.12103.
111. Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. *Proc Natl Acad Sci USA*. 2004;101:6659–6663. doi: 10.1073/pnas.0308291101.
112. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. *Int J Obes (Lond)*. 2005;29:1153–1167. doi: 10.1038/sj.ijo.0802982.
113. Wing RR, Phelan S. Long-term weight loss maintenance. *Am J Clin Nutr*. 2005;82(suppl 1):222S–225S.
114. Avolio AP, Clyde KM, Beard TC, Cooke HM, Ho KK, O'Rourke MF. Improved arterial distensibility in normotensive subjects on a low salt diet. *Arteriosclerosis*. 1986;6:166–169.
115. Dickinson KM, Keogh JB, Clifton PM. Effects of a low-salt diet on flow-mediated dilatation in humans. *Am J Clin Nutr*. 2009;89:485–490. doi: 10.3945/ajcn.2008.26856.
116. He FJ, Marciniak M, Visagie E, Markandu ND, Anand V, Dalton RN, MacGregor GA. Effect of modest salt reduction on blood pressure, urinary albumin, and pulse wave velocity in white, black, and Asian mild hypertensives. *Hypertension*. 2009;54:482–488. doi: 10.1161/HYPERTENSIONAHA.109.133223.
117. Todd AS, Macginley RJ, Schollum JB, Johnson RJ, Williams SM, Sutherland WH, Mann JI, Walker RJ. Dietary salt loading impairs arterial vascular reactivity. *Am J Clin Nutr*. 2010;91:557–564. doi: 10.3945/ajcn.2009.28645.
118. Jablonski KL, Fedorova OV, Racine ML, Geolfos CJ, Gates PE, Chonchol M, Fleenor BS, Lakatta EG, Bagrov AY, Seals DR. Dietary sodium restriction and association with urinary marinobufagenin, blood pressure, and aortic stiffness. *Clin J Am Soc Nephrol*. 2013;8:1952–1959. doi: 10.2215/CJN.00900113.
119. Gates PE, Tanaka H, Hiatt WR, Seals DR. Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. *Hypertension*. 2004;44:35–41. doi: 10.1161/01.HYP.0000132767.74476.64.
120. McMahon EJ, Bauer JD, Hawley CM, Isbel NM, Stowasser M, Johnson DW, Campbell KL. A randomized trial of dietary sodium restriction in CKD. *J Am Soc Nephrol*. 2013;24:2096–2103. doi: 10.1681/ASN.2013030285.
121. McDonough AA, Veiras LC, Guevara CA, Ralph DL. Cardiovascular benefits associated with higher dietary K+ vs. lower dietary Na+: evidence from population and mechanistic studies. *Am J Physiol Endocrinol Metab*. 2017;312:E348–E356. doi: 10.1152/ajpendo.00453.2016.
122. Matthesen SK, Larsen T, Vase H, Lauridsen TG, Pedersen EB. Effect of potassium supplementation on renal tubular function, ambulatory blood pressure and pulse wave velocity in healthy humans. *Scand J Clin Lab Invest*. 2012;72:78–86. doi: 10.3109/00365513.2011.635216.
123. Karppanen H, Mervaala E. Sodium intake and hypertension. *Prog Cardiovasc Dis*. 2006;49:59–75. doi: 10.1016/j.pcad.2006.07.001.
124. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. *Pharmacol Rev*. 2000;52:673–751.
125. Pietta PG. Flavonoids as antioxidants. *J Nat Prod*. 2000;63:1035–1042.
126. Nestel P, Fujii A, Zhang L. An isoflavone metabolite reduces arterial stiffness and blood pressure in overweight men and postmenopausal women. *Atherosclerosis*. 2007;192:184–189. doi: 10.1016/j.atherosclerosis.2006.04.033.
127. Heiss C, Sansone R, Karimi H, Krabbe M, Schuler D, Rodriguez-Mateos A, Kraemer T, Cortese-Krott MM, Kuhnle GG, Spencer JP, Schroeter H, Merx MW, Kelm M; FLAVIOLA Consortium, European Union 7th Framework Program. Impact of cocoa flavanol intake on age-dependent vascular stiffness in healthy men: a randomized, controlled, double-masked trial. *Age (Dordr)*. 2015;37:9794. doi: 10.1007/s11357-015-9794-9.
128. Grassi D, Desideri G, Necozione S, di Giosia P, Barnabei R, Allegaert L, Bernaert H, Ferri C. Cocoa consumption dose-dependently improves flow-mediated dilation and arterial stiffness decreasing blood pressure in healthy individuals. *J Hypertens*. 2015;33:294–303. doi: 10.1097/HJH.0000000000000412.
129. Curtis PJ, Potter J, Kroon PA, Wilson P, Dhatariya K, Sampson M, Cassidy A. Vascular function and atherosclerosis progression after 1 y of flavonoid intake in statin-treated postmenopausal women with type 2 diabetes: a double-blind randomized controlled trial. *Am J Clin Nutr*. 2013;97:936–942. doi: 10.3945/ajcn.112.043745.
130. Aatola H, Koivistoinen T, Hutri-Kähönen N, Juonala M, Mikkilä V, Lehtimäki T, Viikari JS, Raitakari OT, Kähönen M. Lifetime fruit and vegetable consumption and arterial pulse wave velocity in adulthood: the Cardiovascular Risk in Young Finns Study. *Circulation*. 2010;122:2521–2528. doi: 10.1161/CIRCULATIONAHA.110.969279.
131. Ndanuko RN, Tapsell LC, Charlton KE, Neale EP, Batterham MJ. Dietary patterns and blood pressure in adults: a systematic review and meta-analysis of randomized controlled trials. *Adv Nutr*. 2016;7:76–89. doi: 10.3945/an.115.009753.
132. Asmar R. Effect of antihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: clinical implications. *Am J Cardiovasc Drugs*. 2001;1:387–397.
133. Kähönen M, Ylitalo R, Kööbi T, Turjanmaa V, Ylitalo P. Influence of captopril, propranolol, and verapamil on arterial pulse wave velocity and other cardiovascular parameters in healthy volunteers. *Int J Clin Pharmacol Ther*. 1998;36:483–489.
134. Kelly R, Daley J, Avolio A, O'Rourke M. Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. *Hypertension*. 1989;14:14–21.
135. Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. *Am J Cardiol*. 1991;68:61–64.

136. Tedeschi C, Guarini P, Giordano G, Messina V, Cicatiello AM, Iovino L, Tagliamonte MR. Effects of nicardipine on intimal-medial thickness and arterial distensibility in hypertensive patients. Preliminary results after 6 months. *Int Angiol*. 1993;12:344–347.
137. Asmar RG, Benetos A, Chaouche-Teyara K, Raveau-Landon CM, Safar ME. Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. *Am J Cardiol*. 1993;72:794–798.
138. Benetos A, Cambien F, Gautier S, Ricard S, Safar M, Laurent S, Lacolley P, Poirier O, Topouchian J, Asmar R. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. *Hypertension*. 1996;28:1081–1084.
139. Benetos A, Asmar R, Vasmant D, Thiéry P, Safar M. Long lasting arterial effects of the ACE inhibitor ramipril. *J Hum Hypertens*. 1991;5:363–368.
140. Heesen WF, Beltman FW, Smit AJ, May JF, de Graeff PA, Muntinga JH, Havinga TK, Schuurman FH, van der Veur E, Meyboom-de Jong B, Lie KI. Reversal of pathophysiologic changes with long-term lisinopril treatment in isolated systolic hypertension. *J Cardiovasc Pharmacol*. 2001;37:512–521.
141. Mitchell GF, Dunlap ME, Warnica W, Ducharme A, Arnold JM, Tardif JC, Solomon SD, Domanski MJ, Jablonski KA, Rice MM, Pfeffer MA; Prevention of Events With Angiotensin-Converting Enzyme Inhibition Investigators. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. *Hypertension*. 2007;49:1271–1277. doi: 10.1161/HYPERTENSIONAHA.106.085738.
142. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. *Arterioscler Thromb Vasc Biol*. 2005;25:932–943. doi: 10.1161/01.ATV.0000160548.78317.29.
143. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. *J Am Coll Cardiol*. 2009;54:505–512. doi: 10.1016/j.jacc.2009.03.066.
144. Ichihara A, Hayashi M, Koura Y, Tada Y, Hirota N, Saruta T. Long-term effects of intensive blood-pressure lowering on arterial wall stiffness in hypertensive patients. *Am J Hypertens*. 2003;16(11 pt 1):959–965.
145. Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. *Nat Rev Cardiol*. 2011;8:13–28. doi: 10.1038/nrcardio.2010.162.
146. Muramatsu J, Kobayashi A, Hasegawa N, Yokouchi S. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin. *Atherosclerosis*. 1997;130:179–182.
147. Orr JS, Dengo AL, Rivero JM, Davy KP. Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. *Hypertension*. 2009;54:763–768. doi: 10.1161/HYPERTENSIONAHA.109.138248.
148. Pirro M, Schillaci G, Mannarino MR, Savarese G, Vaudo G, Siepi D, Paltriccia R, Mannarino E. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. *Nutr Metab Cardiovasc Dis*. 2007;17:436–441. doi: 10.1016/j.numecd.2006.02.009.
149. Kanaki AI, Sarafidis PA, Georgianos PI, Kanavos K, Tziolas IM, Zebekakis PE, Lasaridis AN. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. *Am J Hypertens*. 2013;26:608–616. doi: 10.1093/ajh/hps098.
150. Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, Saruta T. Long-term effects of statins on arterial pressure and stiffness of hypertensives. *J Hum Hypertens*. 2005;19:103–109. doi: 10.1038/sj.jhh.1001786.
151. Raison J, Rudnichi A, Safar ME. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. *J Hum Hypertens*. 2002;16:705–710. doi: 10.1038/sj.jhh.1001470.
152. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, Kingwell BA. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. *J Am Coll Cardiol*. 2002;39:1020–1025.
153. Lunder M, Janić M, Jug B, Sabovič M. The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial. *Eur J Intern Med*. 2012;23:261–266. doi: 10.1016/j.ejim.2011.11.011.
154. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell*. 2013;153:1194–1217. doi: 10.1016/j.cell.2013.05.039.
155. Martens CR, Seals DR. Practical alternatives to chronic caloric restriction for optimizing vascular function with ageing. *J Physiol*. 2016;594:7177–7195. doi: 10.1113/JP272348.
156. Joannidès R, Monteil C, de Ligny BH, Westeel PF, Iacob M, Thervet E, Barbier S, Bellien J, Lebranchu Y, Seguin SG, Thuillez C, Godin M, Etienne I. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. *Am J Transplant*. 2011;11:2414–2422. doi: 10.1111/j.1600-6143.2011.03697.x.
157. Lesniewski LA, Seals DR, Walker AE, Henson GD, Blimline MW, Trott DW, Bosshardt GC, LaRocca TJ, Lawson BR, Zigler MC, Donato AJ. Dietary rapamycin supplementation reverses age-related vascular dysfunction and oxidative stress, while modulating nutrient-sensing, cell cycle, and senescence pathways. *Aging Cell*. 2017;16:17–26. doi: 10.1111/acel.12524.
158. Soefje SA, Karnad A, Brenner AJ. Common toxicities of mammalian target of rapamycin inhibitors. *Target Oncol*. 2011;6:125–129. doi: 10.1007/s11523-011-0174-9.
159. Lamming DW, Ye L, Sabatini DM, Baur JA. Rapalogs and mTOR inhibitors as anti-aging therapeutics. *J Clin Invest*. 2013;123:980–989. doi: 10.1172/JCI64099.
160. Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M, Rees DA. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. *J Clin Endocrinol Metab*. 2010;95:722–730. doi: 10.1210/jc.2009-1985.
161. Mattison JA, Wang M, Bernier M, et al. Resveratrol prevents high fat/sucrose diet-induced central arterial wall inflammation and stiffening in nonhuman primates. *Cell Metab*. 2014;20:183–190. doi: 10.1016/j.cmet.2014.04.018.
162. Liu M, Wilk SA, Wang A, Zhou L, Wang RH, Ogawa W, Deng C, Dong LQ, Liu F. Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. *J Biol Chem*. 2010;285:36387–36394. doi: 10.1074/jbc.M110.169284.
163. Imai S, Yoshino J. The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing. *Diabetes Obes Metab*. 2013;15(suppl 3):26–33. doi: 10.1111/dom.12171.
164. de Picciotto NE, Gano LB, Johnson LC, Martens CR, Sindler AL, Mills KF, Imai S, Seals DR. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. *Aging Cell*. 2016;15:522–530. doi: 10.1111/acel.12461.
165. Martens C, Denman B, M. M, Armstrong M, Reisdorph N, McQueen M, Chonchol M, Seals DR. Nicotinamide riboside supplementation reduces aortic stiffness and blood pressure in middle-aged and older adults. *Artery Res*. 2017;20:49 [abstract].
166. Wong M, Oakley SP, Young L, Jiang BY, Wierzbicki A, Panayi G, Chowienczyk P, Kirkham B. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2009;68:1277–1284. doi: 10.1136/ard.2007.086157.
167. Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. *Hypertension*. 2010;55:333–338. doi: 10.1161/HYPERTENSIONAHA.109.143982.
168. Mäki-Petäjä KM, Hall FC, Booth AD, Wallace SM, Yasmin, Bearcroft PW, Harish S, Furlong A, McEniery CM, Brown J, Wilkinson IB. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. *Circulation*. 2006;114:1185–1192. doi: 10.1161/CIRCULATIONAHA.105.601641.
169. Ridke PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med*. 2017;377:1119–1131. doi: 10.1056/NEJMoa1707914.
170. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. *Diabetes Care*. 2003;26:2493–2499.
171. Ryan KE, McCance DR, Powell L, McMahon R, Trimble ER. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. *Atherosclerosis*. 2007;194:e123–e130. doi: 10.1016/j.atherosclerosis.2006.11.007.
172. Kernan WN, Viscoli CM, Furie KL, et al; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. *N Engl J Med*. 2016;374:1321–1331. doi: 10.1056/NEJMoa1506930.
173. Kania DS, Smith CT, Nash CL, Gonzalvo JD, Bittner A, Shepler BM. Potential new treatments for diabetic kidney disease. *Med Clin North Am*. 2013;97:115–134. doi: 10.1016/j.mcna.2012.10.004.

174. King TE Jr, Bradford WZ, Castro-Bernardini S, et al; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med*. 2014;370:2083–2092. doi: 10.1056/NEJMoa1402582.
175. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. *Br J Pharmacol*. 2001;133:687–694. doi: 10.1038/sj.bjp.0704131.
176. Jablonski KL, Chonchol M. Vascular calcification in end-stage renal disease. *Hemodial Int*. 2013;17(suppl 1):S17–S21. doi: 10.1111/hdi.12084.
177. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM; American Heart Association. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. *Hypertension*. 2006;47:296–308. doi: 10.1161/01.HYP.0000202568.01167.B6.
178. Brook RD, Appel LJ, Rubenfire M, Ogedegbe G, Bisognano JD, Elliott WJ, Fuchs FD, Hughes JW, Lackland DT, Staffileno BA, Townsend RR, Rajagopalan S; American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association. *Hypertension*. 2013;61:1360–1383. doi: 10.1161/HYP.0b013e318293645f.
179. Seals DR, Desouza CA, Donato AJ, Tanaka H. Habitual exercise and arterial aging. *J Appl Physiol (1985)*. 2008;105:1323–1332. doi: 10.1152/japplphysiol.90553.2008.
180. Santos-Parker JR, LaRocca TJ, Seals DR. Aerobic exercise and other healthy lifestyle factors that influence vascular aging. *Adv Physiol Educ*. 2014;38:296–307. doi: 10.1152/advan.00088.2014.
181. Fleenor BS, Marshall KD, Durrant JR, Lesniewski LA, Seals DR. Arterial stiffening with ageing is associated with transforming growth factor-β1-related changes in adventitial collagen: reversal by aerobic exercise. *J Physiol*. 2010;588(pt 20):3971–3982. doi: 10.1113/jphysiol.2010.194753.
182. Nosaka T, Tanaka H, Watanabe I, Sato M, Matsuda M. Influence of regular exercise on age-related changes in arterial elasticity: mechanistic insights from wall compositions in rat aorta. *Can J Appl Physiol*. 2003;28:204–212.
183. Rider OJ, Tayal U, Francis JM, Ali MK, Robinson MR, Byrne JP, Clarke K, Neubauer S. The effect of obesity and weight loss on aortic pulse wave velocity as assessed by magnetic resonance imaging. *Obesity (Silver Spring)*. 2010;18:2311–2316. doi: 10.1038/oby.2010.64.
184. Jablonski KL, Racine ML, Geolfos CJ, Gates PE, Chonchol M, McQueen MB, Seals DR. Dietary sodium restriction reverses vascular endothelial dysfunction in middle-aged/older adults with moderately elevated systolic blood pressure. *J Am Coll Cardiol*. 2013;61:335–343. doi: 10.1016/j.jacc.2012.09.010.
185. Oberleithner H, Riethmüller C, Schillers H, MacGregor GA, de Wardener HE, Hausberg M. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. *Proc Natl Acad Sci USA*. 2007;104:16281–16286. doi: 10.1073/pnas.0707791104.
186. Squadrito F, Altavilla D, Morabito N, Crisafulli A, D'Anna R, Corrado F, Ruggeri P, Campo GM, Calapai G, Caputi AP, Squadrito G. The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. *Atherosclerosis*. 2002;163:339–347.
187. Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, Sies H, Kwik-Uribe C, Schmitz HH, Kelm M. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. *Proc Natl Acad Sci USA*. 2006;103:1024–1029. doi: 10.1073/pnas.0510168103.
188. Bazzano LA, Serdula MK, Liu S. Dietary intake of fruits and vegetables and risk of cardiovascular disease. *Curr Atheroscler Rep*. 2003;5:492–499.
189. Holt EM, Steffen LM, Moran A, Basu S, Steinberger J, Ross JA, Hong CP, Sinaiko AR. Fruit and vegetable consumption and its relation to markers of inflammation and oxidative stress in adolescents. *J Am Diet Assoc*. 2009;109:414–421. doi: 10.1016/j.jada.2008.11.036.
190. Boutouyrie P, Lacolley P, Briet M, Regnault V, Stanton A, Laurent S, Mahmud A. Pharmacological modulation of arterial stiffness. *Drugs*. 2011;71:1689–1701. doi: 10.2165/11593790-000000000-00000.
191. John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, Schmieder RE. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. *Circulation*. 1998;98:211–216.
192. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Zucker IH. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. *Circulation*. 2005;112:1763–1770. doi: 10.1161/CIRCULATIONAHA.105.552174.
193. Wang J, Xu J, Zhou C, Zhang Y, Xu D, Guo Y, Yang Z. Improvement of arterial stiffness by reducing oxidative stress damage in elderly hypertensive patients after 6 months of atorvastatin therapy. *J Clin Hypertens (Greenwich)*. 2012;14:245–249. doi: 10.1111/j.1751-7176.2012.00600.x.
194. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. *Diabetes*. 2006;55:496–505.
195. Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, Förstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. *Circulation*. 2002;106:1652–1658.
196. Pearson KJ, Baur JA, Lewis KN, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. *Cell Metab*. 2008;8:157–168. doi: 10.1016/j.cmet.2008.06.011.
197. Appel LJ, Frohlich ED, Hall JE, Pearson TA, Sacco RL, Seals DR, Sacks FM, Smith SC Jr, Vafiadis DK, Van Horn LV. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. *Circulation*. 2011;123:1138–1143.
198. Mohan S, Campbell NR, Willis K. Effective population-wide public health interventions to promote sodium reduction. *CMAJ*. 2009;181:605–609. doi: 10.1503/cmaj.090361.
199. Seals DR. Translational physiology: from molecules to public health. *J Physiol*. 2013;591:3457–3469. doi: 10.1113/jphysiol.2013.253195.
200. Vranish JR, Bailey EF. Daily respiratory training with large intrathoracic pressures, but not large lung volumes, lowers blood pressure in normotensive adults. *Respir Physiol Neurobiol*. 2015;216:63–69. doi: 10.1016/j.resp.2015.06.002.
201. Vranish JR, Bailey EF. Inspiratory muscle training improves sleep and mitigates cardiovascular dysfunction in obstructive sleep apnea. *Sleep*. 2016;39:1179–1185. doi: 10.5665/sleep.5826.
202. Brunt VE, Howard MJ, Francisco MA, Ely BR, Minson CT. Passive heat therapy improves endothelial function, arterial stiffness and blood pressure in sedentary humans. *J Physiol*. 2016;594:5329–5342. doi: 10.1113/JP272453.
203. Striepe K, Jumar A, Ott C, Karg MV, Schneider MP, Kannenkeril D, Schmieder RE. Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus. *Circulation*. 2017;136:1167–1169. doi: 10.1161/CIRCULATIONAHA.117.029529.
204. Terentes-Printzios D, Vlachopoulos C, Xaplanteris P, Ioakeimidis N, Aznaouridis K, Baou K, Kardara D, Georgiopoulos G, Georgakopoulos C, Tousoulis D. Cardiovascular risk factors accelerate progression of vascular aging in the general population results from the CRAVE study (Cardiovascular Risk Factors Affecting Vascular Age). *Hypertension*. 2017;70:1057–1064. doi: 10.1161/HYPERTENSIONAHA.117.09633.